Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial.
Lu XieJie XuXin SunXiaodong TangTaiqiang YanRongli YangWei GuoPublished in: The oncologist (2018)
For advanced osteosarcoma progressing upon chemotherapy, antiangiogenesis tyrosine kinase inhibitors (TKIs) have been proved to be effective in prolonging the progression-free survival in previous multicenter trials and have been included into new National Comprehensive Cancer Network guidelines as second-line therapy. Apatinib is a TKI that specifically inhibits vascular endothelial growth factor receptor-2, which is domestically made in China. This phase II trial supports the use of apatinib in patients with advanced osteosarcoma progressing after chemotherapy.
Keyphrases
- phase ii
- clinical trial
- vascular endothelial growth factor
- open label
- free survival
- double blind
- locally advanced
- placebo controlled
- papillary thyroid
- endothelial cells
- phase iii
- clinical practice
- squamous cell carcinoma
- stem cells
- pain management
- squamous cell
- advanced non small cell lung cancer
- cell therapy
- chemotherapy induced
- mesenchymal stem cells
- chronic pain
- bone marrow